Local, national & international business news and events.
City and state officials are trying to recover millions from quick deals made during the worst weeks of the pandemic this spring. — NYT: Top Stories
Application Based on Overall Survival and Progression-Free Survival Data Comparing KEYTRUDA Plus Chemotherapy to Chemotherapy Alone From Pivotal Phase 3 KEYNOTE-590 Trial KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.
Environmental goals build on previously announced D&I commitments to enhance the company’s enterprise ESG efforts PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced it is strengthening its commitment to environmental sustainability on a global basis by setting new 2030 and 2040
Design Innovations Reduce Costs by Half, Decrease Production Time, and Increase Reliability of Spacecraft Solutions MONTVILLE, N.J.–(BUSINESS WIRE)–#JAXA—Marotta Controls, a rapidly growing aerospace and defense supplier based in New Jersey, today announced that it will be supplying critical system valves to Honeybee
Up to a foot of snow is forecasted in New York City between Wednesday afternoon and Thursday evening. — NYT: Top Stories
How a leading man of legal journalism lost his sweetest gig. — NYT: Top Stories
SINGAPORE–(BUSINESS WIRE)–Vonage (Nasdaq: VG), a global leader in cloud communications helping businesses accelerate their digital transformation, is powering Japan’s leading online sales system provider bellFace’s video call solution. bellFace enables companies’ sales and customer support teams to maximise sales results and productivity
Reducing trade with China was supposed to happen in 2020. But demand for Chinese goods has soared amid pandemic lockdowns. — NYT: Top Stories
TOKYO & MUNICH & BASKING RIDGE, N.J. — (BUSINESS WIRE) — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of TROPION-Lung01, a global pivotal phase 3 head-to-head study of datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 directed antibody